$PLRZ News

Polyrizon Signs Clinical Trial Agreement With A U.S. Clinical Research Site Specializing In Allergy Studies For The NASARIX Allergy Blocker Clinical Program

Polyrizon Amends U.S. Patent Application Claims For Its Proprietary Intranasal Drug Delivery Platform

Polyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery Platform

Polyrizon Files European Patent Application For Trap & Target Platform Technology

Polyrizon Ltd. Announces Closing of $3.5 Million Registered Direct and Private Placements

Polyrizon Ltd. Announces $3.5 Million Registered Direct Offering and Private Placement

Polyrizon Announces Direct Offering And Concurrent Private Placement With Unnamed Institutional Investor For A Combined ~$3.5M, Transactions To Close April 8

Polyrizon Provides 2025 and Recent Highlights

Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025

Polyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced eVTOL Drones for Defense and Urban Air Mobility Applications

Polyrizon Signs Memorandum Of Understanding To Acquire Up To 20% Of Colugo Systems For $6M In Potential Cash/Share Issuance Combination

Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program

Polyrizon Signs Deal With Contract Research Organization To Carry Out Package Of Preclinical Biocompatibility Studies In Accordance With ISO 10993 Standards, GLP Requirements

Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study

Polyrizon Announces Production Of Good Manufacturing Practice Batch Of Clinical Trial Material For Its Lead Product Candidate

Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product

Polyrizon Announces Results From Comparative Study Evaluating Regional Nasal Deposition Profile Of Naloxone Formulation Versus Commercial Reference Product

Moonage Media Spotlights Polyrizon (Nasdaq: PLRZ): Unveils NASARIX™, Drug-Free Allergy Blocker

Polyrizon Intends to Secure Controlling Stake in Profitable Private Jet Operator

Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI